Beamion LUNG-1 study results for zongertinib in treatment-naïve patients with HER2-mutant advanced NSCLC published in The New England of Journal of Medicine April 16, 2026
ACHIEVE-4, the longest Phase 3 study of Lilly’s Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health April 16, 2026
It’s Time to Pass Go! MONOPOLY Big Board Bucks™ by Aristocrat Gaming™ Makes Its Official Debut at Yaamava’ Resort & Casino April 16, 2026
Artmarket.com news: Artprice confirms the success of Artprice News, the world’s first news agency entirely dedicated to art and its market, available in 11 languages and 122 countries, with Cision PR Newswire and X April 15, 2026
L’Oréal Paris Spotlights the Hidden Impact of Street Harassment with New “Missed Opportunities” Campaign April 15, 2026
Phiusion Labs Inc. Announces Strategic Distribution Partnership with Proteos Biotech S.L. for PBSerum® in the United States and Canada April 13, 2026
AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026 April 13, 2026
Trinchero Family Wine & Spirits Accelerates Non-Alcoholic Leadership Through Exclusive Partnership with Libby April 10, 2026
Florida Plastic Surgery & Med Spa Earns Top Honors in 2026 Sarasota Herald-Tribune Community Choice Awards April 10, 2026
Foundayo™ (orforglipron), Lilly’s new oral GLP-1 pill for weight loss, now available in the U.S. April 9, 2026